Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex

• Autores principales: Maxim A.X. Tollenaere (Autor), Christina Mølck (Autor), Ian Henderson (Autor), Scott Pollack (Autor), Philip Addis (Autor), Helle Heibroch Petersen (Autor), Hanne Norsgaard (Autor)
• Formato: Libro
• Publicado: Elsevier, 2023-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of IL-13 with IL-13Rα1 and subsequent signaling....